Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study.

ABSTRACT:

Background/aims

Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared the risks of EHM and intrahepatic malignancy (IHM) between entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment.

Methods

Using data from the National Health Insurance Service of Korea, this nationwide cohort study included treatment-naïve CHB patients who initiated ETV (n=24,287) or TDF (n=29,199) therapy between 2012 and 2014. The primary outcome was the development of any primary EHM. Secondary outcomes included overall IHM development. E-value was calculated to assess the robustness of results to unmeasured confounders.

Results

The median follow-up

SUBMITTER: Hur MH 

PROVIDER: S-EPMC11261230 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature